Table 5.
Factors Associated with Adverse Outcomes (Composite Outcomes) at 30 Days
| Total N = 205 (%) | Adverse Events 30 Days N = 39 (%) | P value | Multiple Logistic Regression Odds Ratio (95% CI) | ||
|---|---|---|---|---|---|
| Gender, female | 114 (55.61) | 24 (61.54) | 0.41 | ||
| Medication | |||||
| Diuretic | 59 (28.78) | 10 (25.64) | 0.63 | ||
| Angiotensin-converting enzyme inhibitor | 14 (6.82) | 2 (5.13) | 1 | ||
| Angiotensin II receptor blocker | 65 (31.70) | 16 (41.03) | 0.17 | 0.59 | 0.58–2.77 |
| Calcium channel blocker | 63 (30.73) | 11 (28.21) | 0.83 | ||
| Beta-blocker | 102 (49.75) | 20 (51.28) | 0.83 | ||
| Amiodarone | 5 (2.43) | 2 (5.13) | 0.24 | ||
| Digoxin | 5 (2.43) | 0 | 1 | ||
| Comorbidity | |||||
| Cardiovascular disease | 76 (37.07) | 18 (46.15) | 0.19 | 0.68 | 0.61–2.78 |
| Hypertension | 165 (80.48) | 35 (89.74) | 0.12 | 0.88 | 0.52–5.51 |
| Dyslipidemia | 100 (48.78) | 21 (53.85) | 0.48 | ||
| Diabetes mellitus | 76 (37.07) | 17 (43.59) | 0.35 | ||
| Heart failure | 16 (7.80) | 4 (10.26) | 0.51 | ||
| Left ventricular ejection fraction <40% | 6 (2.92) | 2 (5.13) | 0.37 | ||
| Pericarditis | 1 (0.48) | 0 | 1 | ||
| Valvular heart disease | 7 (3.41) | 1 (2.56) | 1 | ||
| Cerebrovascular disease | 26 (12.68) | 5 (12.82) | 0.98 | ||
| Chronic obstructive pulmonary disease | 4 (1.95) | 0 | 1 | ||
| End-stage renal disease with dialysis | 9 (4.39) | 5 (12.82) | 0.01 | 2.34 | 1.31–20.88 |
| Thyroid disease | 15 (7.31) | 5 (12.82) | 0.14 | 1.11 | 0.60–6.34 |
| Alcohol | 7 (3.41) | 1 (2.56) | 1 | ||
| Smoking | 10 (4.87) | 3 (7.69) | 0.41 | ||